Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 lilotomab satetraxetan - Nordic Nanovector

Next Previous
X
Search
Drug Profile

Lutetium-177 lilotomab satetraxetan - Nordic Nanovector

Alternative Names: 177Lu-DOTA-HH1; 177Lu-Dota-tetulomab; 177Lu-lilotomab satetraxetan; 177Lu-tetraxetan-tetulomab; 177Lutetulomab; Betalutin; HH1; Lilotomab - Nordic Nanovector; Lilotomab-satetraxetan-177Lu; Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector; Lutetium 177Lu lilotomab satetraxetan; Lutetium-177-tetulomab; Lymrit 37-02

Latest Information Update: 24 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nordic Nanovector
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Follicular lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Follicular lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 18 Apr 2023 Lutetium-177 lilotomab satetraxetan - Nordic Nanovector is available for licensing as of 24 Apr 2023. https://www.nordicnanovector.com/
  • 18 Apr 2023 Efficacy and adverse events data from a phase II PARADIGME trial in Follicular lymphoma released by Nordic Nanovector
  • 27 Oct 2022 Nordic Nanovector completes a phase I/II trial in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA, Turkey, Switzerland, Singapore, Netherlands, South Korea, Israel, Ireland, Hungary, Hungary, France, Finland, Australia, Belgium, Canada, Croatia, Denmark, Spain, Austria, Germany (IV) (NCT01796171)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top